Cell Therapies Pty Ltd is pleased to announce that Dr Christian Behrenbruch has been appointed as Chairman of the Melbourne-based life sciences company. Dr Behrenbruch will also serve as a nominee non-executive director on behalf of the Peter MacCallum Cancer Centre, the major shareholder of Cell Therapies.
Dr Behrenbruch has a demonstrated track record of building successful organisations in the life sciences and healthcare arena. He is currently the Chief Executive Officer of ImaginAb, Inc. a venture-backed biotechnology company based in California and Singapore. Previous executive roles have included Managing Partner at Momentum Biosciences, Vice President at Siemens Healthcare, Sr. VP at CTI Molecular Imaging (sold to Siemens in a $1.1Bn transaction in 2005) and CEO of Mirada Solutions, a successful UK-based radiology company that was spun-out of the University of Oxford.
Dr Behrenbruch completed his undergraduate studies at Monash University, received a D.Phil (Ph.D) in biomedical engineering from Oxford University and an MBA jointly awarded by New York University and the London School of Economics. Dr Behrenbruch has also held several academic appointments, including a faculty position in the Department of Medical and Molecular Pharmacology at the University of California, Los Angeles. He is currently an adjunct professor and member of the Industry Advisory Board at RMIT University’s College of Business (Melbourne).
“We’re delighted with this appointment as Dr Behrenbruch brings a strong combination of academic excellence in healthcare, understanding of the regulatory challenges of product development and a proven track record as a ‘serial entrepreneur’ in financing and nurturing early-stage companies,” said Ray Wood, CEO of Cell Therapies.
“Cell Therapies has done a remarkable job of building a unique life sciences company with an unmatched track record in manufacturing and deploying complex products in the cell therapies space,” commented Dr. Behrenbruch. “The company has exciting growth potential in terms of new products and regional market opportunities as this ‘pillar’ of healthcare starts to yield technologies with significant therapeutic potential.”
For more information, contact Ray Wood at Cell Therapies on: 61 3 9656 1615 or email@example.com / www.celltherapies.com.au